Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Surg Today ; 2024 May 04.
Artigo em Inglês | MEDLINE | ID: mdl-38702438

RESUMO

PURPOSE: There have been no adequate comparisons of the efficacy, safety, and efficiency of analgesia after laparoscopic colorectal resection (LAC), with and without epidural anesthesia (EDA). METHODS: This was a multicenter prospective observational study of patients undergoing LAC. The primary end point was the mean visual analog scale (VAS) score on postoperative days (PODs) 1-7. The secondary end points were the highest VAS, complication rate, days to first ambulation and fatigue, length of hospital stay, and time to commencement of surgery. RESULTS: We compared an EDA group (Group E, n = 48) and a no-EDA group (Group O, n = 48) after matching. The mean VAS was not significantly different between the groups (28.7 vs. 30.1, p = 0.288). On assessing the secondary end points, the highest VAS was not significantly different between the groups. In fact, the VAS was lower in Group E only on POD 2. There was no difference in the incidence of complications, the time to first postoperative evacuation was shorter in Group E, and postoperative hospitalization was similar. The time to surgery was shorter in Group O. CONCLUSION: These results suggest that LAC without EDA is a feasible option, but with the early and regular use of adjunctive measures to provide more stable analgesia.

2.
Int J Surg Case Rep ; 102: 107840, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36577264

RESUMO

INTRODUCTION: Intravenous tumor thrombosis is a rare condition in colorectal cancer and shows a locally aggressive biological behavior. We herein report three cases of colorectal cancer with tumor thrombosis in the inferior mesenteric vein (IMV) treated by colorectal resection combined with resection of the IMV under laparoscopic surgery. CASE PRESENTATION: In these three colorectal cancer patients with IMV tumor thrombus, IMV tumor thrombus was detected in all instances on preoperative computed tomography. Preoperative chemotherapy was also performed in one patient with concurrent liver metastasis. All patients underwent laparoscopic locally R0 resection; however, the pathological findings showed a positive margin for IMV resection in all patients. CLINICAL DISCUSSION: We reviewed 19 previously reported cases along with our 3 present cases and clarified the characteristics of colorectal cancer accompanied by IMV tumor thrombosis. IMV tumor thrombosis may be a risk factor for liver metastasis and R1 resection, and systemic treatment, including neoadjuvant chemotherapy (NAC), may be quite important. CONCLUSION: IMV tumor thrombosis may have a tendency to cause hematogenous metastasis. Systemic therapy, including NAC, may be useful, but since this is a rare condition, the accumulation of further cases is needed.

3.
Gan To Kagaku Ryoho ; 50(13): 1563-1565, 2023 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-38303342

RESUMO

A 77-year-old man visited a clinic because of nausea and chest discomfort. On blood test, hepatobiliary enzymes were elevated, and he referred to our hospital. Contrast-enhanced CT revealed stenosis of the extrahepatic bile duct and brush cytology of the bile duct showed adenocarcinoma. We therefore performed pancreatoduodenectomy for extrahepatic bile duct cancer. Pathological diagnosis was small cell neuroendocrine carcinoma, pT3N2M0, Stage ⅢA. The patient did not receive adjuvant chemotherapy and 3 months later contrast-enhanced CT and MRI showed multiple liver metastases. The patient was treated with cisplatin plus irinotecan in the first-line, cisplatin plus etoposide in the second-line, and amrubicin in the third-line and accordingly he died 1 year and 3 months after the surgery. Chemotherapy for neuroendocrine carcinoma of the bile duct is recommended as in small cell lung cancer, but the prognosis is extremely poor. We report this case with a review of some of the literature.


Assuntos
Adenocarcinoma , Neoplasias dos Ductos Biliares , Ductos Biliares Extra-Hepáticos , Carcinoma Neuroendócrino , Masculino , Humanos , Idoso , Cisplatino/uso terapêutico , Carcinoma Neuroendócrino/tratamento farmacológico , Carcinoma Neuroendócrino/cirurgia , Ductos Biliares Extra-Hepáticos/cirurgia , Adenocarcinoma/diagnóstico , Neoplasias dos Ductos Biliares/tratamento farmacológico , Neoplasias dos Ductos Biliares/cirurgia , Neoplasias dos Ductos Biliares/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA